Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.59 |
| ▸ | ANPEP | P15144 | 1/20 | 0.56 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26618636 | 1.00 | DNM1 (0.59) | DNM1ANPEPERAP2TSHRROCK2 | |
| SCHEMBL2916825 | 0.85 | DNM1 (0.58) | DNM1ANPEPERAP2TSHRNPC1 | |
| SCHEMBL15819968 | 0.83 | ANPEP (0.59) | DNM1ANPEPERAP2TSHRADRB3 | |
| SCHEMBL6499108 | 0.83 | ANPEP (0.59) | DNM1ANPEPERAP2TSHRADRB3 | |
| SCHEMBL6492794 | 0.83 | ANPEP (0.59) | DNM1ANPEPERAP2TSHRADRB3 | |
| SCHEMBL25121044 | 0.82 | S1PR2 (0.52) | DNM1ANPEPERAP2TSHRADRB3 | |
| SCHEMBL6640768 | 0.81 | CHRM2 (0.62) | DNM1ADRB3CHRM2KMT2AMEN1 | |
| SCHEMBL898462 | 0.81 | ANPEP (0.66) | DNM1ANPEPERAP2TSHRADRB3 | |
| SCHEMBL3709824 | 0.81 | ANPEP (0.56) | DNM1ANPEPERAP2CHRM2DPP7 | |
| SCHEMBL16700680 | 0.81 | GAA (0.65) | DNM1ANPEPERAP2TSHRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296939-A1 | BENZOTHIOPHENE COMPOUND | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2025-09-25 | — | — | US | disclosed |
| EP-4516792-A1 | BENZOTHIOPHENE COMPOUND | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023210740-A1 | BENZOTHIOPHENE COMPOUND | 第一三共株式会社 | 2023-11-02 | — | — | WO | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7402595-B2 | Enzyme inhibitors with isoquinolinone structures | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-22 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
| EP-1597248-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050148624-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1484320-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148624-A1 | Jnk inhibitor | MAPK3, MAPKAPK3, MAPK1 | DNM1 3714/4885ANPEP 3128/4885ERAP2 4606/4885 |
| US-20250296939-A1 | BENZOTHIOPHENE COMPOUND | NFE2L2, KEAP1, BPTF | DNM1 4032/4885ANPEP 4458/4885ERAP2 3677/4885 |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | DNM1 2651/4885ANPEP 3894/4885ERAP2 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.